drugset / Trial / NCT05227690
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2024-08-23
- Completion
- 2024-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emraclidine | Small molecule | 10 mg | Oral |
| Subject | Emraclidine | Small molecule | 30 mg | Oral |